In the latest podcast episode, Optimum Strategic Communications’ Eva Haas gives her thoughts on the trends in the biopharma market for 2023. After the geopolitical upheavals of last year, according to some sources there has been a gradual recovery. For instance an analysis by Clarivate and the BioIndustry Association trade body secured £382 million in […]
Alchemab is a Cambridge biotech that aims to revolutionise drug discovery with a novel alternative to big pharma’s classic “choose a target” approach. Optimum’s Richard Staines caught up with Alchemab’s CEO, Young Kwon, to find out more. The UK has long been a leader in the field of antibody drug technology, and it was British […]
There’s an increasing focus on using drugs to modify the tumour microenvironment, reducing immunosuppression and breaking down the barrier of fibrotic scar tissue that blocks many therapies. Optimum Strategic Communications’ Richard Staines talked to our client iOnctura, about the Company’s plans to use an autotaxin inhibitor to remove this obstacle. Scientists are looking at a […]
No-one is likely to forget the tragic events of 2020 and one company leading efforts to prepare for the next pandemic is Poolbeg Pharma. Optimum Strategic Communications’ Richard Staines interviewed CEO Jeremy Skillington to find the latest insights. Discussions are not about whether another pandemic will happen, but when, as a number of factors converge […]
Investment firms Medicxi has raised $400M for Medicxi IV Fund Markus Kalousek and Andrew Lightfoot have joined BGV as Venture Partner André Leue has joined Bell Rock Capital Management LLP as Portfolio Manager Global Equities Healthcare Evan Castiglia has joined Thuja Healthcare Investors as an Investment Director and Partner Analysts and Banking Dominic Wilson has […]
